Skip to main content Accessibility help
×
Home
  • Print publication year: 2011
  • Online publication date: March 2011

Chapter 3 - Selective serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder

References

AboujaoudeE, BarryJJ, GamelN (2009). Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J Clin Psychopharmacol 29: 51–55.
AbramowitzJS (1997). Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol 65: 44–52.
AckermanDL, GreenlandS (2002). Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychopharmacol 22: 309–317.
AckermanDL, GreenlandS, BystritskyA (1999). Side effects as predictors of drug response in obsessive-compulsive disorder. J Clin Psychopharmacol 19: 459–465.
AlbertU, AgugliaE, MainaG, BogettoF (2002). Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J Clin Psychiatry 63: 1004–1009.
American Psychiatric Association (1987). Diagnostic and Statistical Manual of Mental Disorders, 3rd edn. Washington, DC: American Psychiatric Press.
American Psychiatric Association (2007). Practice Guidelines for the treatment of Patients with Obsessive Compulsive Disorder. Washington, DC: American Psychiatric Press.
ArnoldPD, SicardT, BurroughsE, RichterMA, KennedyJL (2006). Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch Gen Psychiatry 63: 769–776.
AryaDK (1994). Extrapyramidal symptoms with selective serotonin reuptake inhibitors. Br Med J 165: 728–733.
AshtonAK, WeinsteinWL (2002). Cyproheptadine for drug-induced sweating. Am J Psychiatry 159: 874–875.
BallengerJC (1999). Current treatments of the anxiety disorders in adults. Biol Psychiatry 46: 1579–1594.
BaxterLR (2001): Functional imaging of brain systems mediating obsessive-compulsive disorder. In CharneyDS, NestlerEJ, BunneyBS (eds.) Neurobiology of Mental Illness (pp. 534–547). Oxford: Oxford University Press.
BergeronR, RavindranAV, ChaputY, et al. (2002). Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study. J Clin Psychopharmacol 22: 148–154.
BogettoF, AlbertU, MainaG (2002). Sertraline treatment of obsessive-compulsive disorder: efficacy and tolerability of a rapid titration regimen. Eur Neuropsychopharmacol 12: 181–186.
BoyerEW, ShannonM (2005). The serotonin syndrome. N Engl J Med 352: 1112–1120.
ChakrabartyK, BhattacharyyaS, KhannaS, ChristopherR (2005). Glutamatergic dysfunction in OCD. Neuropsychopharmacology 30: 1735–1740.
ClaytonAH, PradkoJF, CroftHA, et al. (2002). Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 63: 357–366.
ClaytonAH, WarnockJK, KornsteinSG, et al. (2004). A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry 65: 62–67.
Clomipramine Collaborative Study Group. (1991). Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 48: 730–738.
CoricV, TaskiranS, PittengerC, et al. (2005). Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 58: 424–428.
CottrauxJ, BouvardMA, MillieryM (2005). Combining pharmacotherapy with cognitive-behavioral interventions for obsessive-compulsive disorder. Cogn Behav Ther 34: 185–192.
CoxBJ, SwinsonRP, MorrisonB, LeePS (1993). Clomipramine, fluoxetine, and behavior therapy in the treatment of obsessive-compulsive disorder: a meta-analysis. J Behav Ther Exp Psychiatry 24: 149–153.
DebattistaC, SolvasonB, PoirierJ, KendrickE, LoraasE (2005). A placebo-controlled, randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunction. J Clin Psychiatry 66: 844–848.
DenysD (2006). Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders. Psychiatr Clin N Am 29: 553–584, xi.
DenysD, van der WeeN, van MegenHJ, WestenbergHG (2003). A double-blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol 23: 568–575.
DenysD, van MegenHJ, van der WeeN, WestenbergHG (2004). A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. J Clin Psychiatry 65: 37–43.
DhillonS, ScottLJ, PloskerGL (2006). Escitalopram: a review of its use in the management of anxiety disorders. CNS Drugs 20: 763–790.
DickelDE, Veenstra-VanderWeeleJ, CoxNJ, et al. (2006). Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder. Arch Gen Psychiatry 63: 778–785.
EddyKT, DutraL, BradleyR, WestenD (2004). A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev 24: 1011–1030.
ErzegovesiS, CavalliniMC, CavediniP, et al. (2001). Clinical predictors of drug response in obsessive-compulsive disorder. J Clin Psychopharmacol 21: 488–492.
Evaluation of Genomic Applications in Practice and Prevention Working Group (2007). Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med 9: 819–825.
FallonBA, LiebowitzMR, CampeasR, et al. (1998). Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study. Arch Gen Psychiatry 55: 918–924.
FederR (1995). Clonidine treatment of excessive sweating. J Clin Psychiatry 56: 35.
FergusonJM (2001). SSRI antidepressant medications: adverse effects and tolerability. J Clin Psychiatry 3: 22–27.
FigeeM, DenysD (2009). New pharmacotherapeutic approaches to obsessive-compulsive disorder. CNS Spectr 14(Suppl 3): 13–23.
FigueroaY, RosenbergDR, BirmaherB, KeshavanMS (1998). Combination treatment with clomipramine and selective serotonin reuptake inhibitors for obsessive-compulsive disorder in children and adolescents. J Child Adolesc Psychopharmacol 8: 61–67.
FinebergNA, GaleTM (2005). Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol 8: 107–129.
FinebergNA, TonnoirB, LemmingO, SteinDJ (2007a). Escitalopram prevents relapse of obsessive-compulsive disorder. Eur Neuropsychopharmacol 17: 430–439.
FinebergNA, PampaloniI, PallantiS, IpserJ, SteinDJ (2007b). Sustained response versus relapse: the pharmacotherapeutic goal for obsessive-compulsive disorder. Int Clin Psychopharmacol 22: 313–322.
FoaEB, KozakMJ, SteketeeGS, McCarthyPR (1992). Treatment of depressive and obsessive-compulsive symptoms in OCD by imipramine and behavior therapy. Br J Clin Psychol 31: 279–292.
FontenelleLF, NascimentoAL, MendlowiczMV, ShavittRG, VersianiM (2007). An update on the pharmacological treatment of obsessive-compulsive disorder. Expert Opin Pharmacother 8: 563–583.
FreemanCP, TrimbleMR, DeakinJF, StokesTM, AshfordJJ (1994). Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. J Clin Psychiatry 55: 301–305.
GarberA, GregoryRJ (1997). Benztropine in the treatment of venlafaxine induced sweating. J Clin Psychiatry 58: 176–177.
GoodmanWK, PriceLH, RasmussenSA, et al. (1989). Efficacy of fluvoxamine in obsessive-compulsive disorder: a double-blind comparison with placebo. Arch Gen Psychiatry 46: 36–44.
GoodmanWK, McDougleCJ, BarrLC, AronsonSC, PriceLH (1993). Biological approaches to treatment-resistant obsessive compulsive disorder. J Clin Psychiatry 54(Suppl): 16–26.
GoodmanWK, KozakMJ, LiebowitzM, WhiteKL (1996). Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. Int Clin Psychopharmacol 11: 21–29.
GramLF, HansenMG, SindrupSH, et al. (1993). Citalopram: interaction studies with levomepromazine, imipramine, and lithium. Ther Drug Monit 15: 18–24.
GrantJE, OdlaugBL, KimSW (2009). N-Acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 66: 756–763.
GrantP, LougeeL, HirschtrittM, SwedoS (2007). An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. Child Adolesc Psychopharmacol 17: 761–767.
GreistJH, JeffersonJW, KobakKA, KatzelnickDJ, SerlinRC (1995a). Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Arch Gen Psychiatry. 52: 53–60.
GreistJH, JenikeMA, RobinsonD, RasmussenSA (1995b). Efficacy of fluvoxamine in obsessive-compulsive disorder: results of a multicentre, double blind, placebo controlled trial. Eur J Clin Res 7: 195–204.
GreistJ, ChouinardG, DuBoffE, et al. (1995c). Double-blind parallel comparison of three doses of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 52: 289–295.
GunnellD, SaperiaJ, AshbyD (2005). Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA’s safety review. BMJ 330: 385.
HarveyAT, PreskornSH (1996). Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. J Clin Psychopharmacol 16: 345–355.
HollanderE, BienstockCA, KoranLM, et al. (2002). Refractory obsessive-compulsive disorder: state-of-the-art treatment. J Clin Psychiatry 63(Suppl 6): 20–29.
HollanderE, KoranLM, GoodmanWK, et al. (2003a). A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry 64: 640–647.
HollanderE, AllenA, SteinerM, et al. (2003b). Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J Clin Psychiatry 64: 1113–1121.
HollanderE, FriedbergJ, WassermanS, et al. (2003c). Venlafaxine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 64: 546–550.
JenikeMA, BaerL, GreistJH (1995a). Clomipramine versus fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacy. J Clin Psychopharmacol 10: 122–124.
JenikeMA, HymanS, BaerL, et al. (1995b). A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. Am J Psychiatry 147: 1209–1215.
JenikeMA, BaerL, MinichielloWE, RauchSL, ButtolphML (1997). Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Am J Psychiatry 154: 1261–1264.
Jiménez-JiménezFJ, PuertasI, de Toledo-HerasM (2004). Drug-induced myoclonus: frequency, mechanisms and management. CNS Drugs 18: 93–104.
JoelD, DoljanskyJ, RozN, RehaviM (2005). Role of the orbital cortex and of the serotonergic system in a rat model of obsessive compulsive disorder. Neuroscience 130: 25–36.
KamijimaK, MurasakiM, AsaiM, et al. (2004). Paroxetine in the treatment of obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study in Japanese patients. Psychiatry Clin Neurosci 58: 427–433.
KatzRJ, DeVeaugh-GeissJ, LandauP (1990). Clomipramine in obsessive-compulsive disorder. Biol Psychiatry 28: 401–414.
KoponenH, LepolaU, LeinonenE, et al. (1997). Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study. Acta Psychiatr Scand 96: 343–346.
KoranLM, McElroySL, DavidsonJR, et al. (1996). Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. J Clin Psychopharmacol 16: 121–129.
KoranLM, SalleeFR, PallantiS (1997). Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Am J Psychiatry 154: 396–401.
KoranLM, HackettE, RubinA, et al. (2002). Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder. Am J Psychiatry 159: 88–95.
KoranLM, AboujaoudeE, BullockKD, et al. (2005). Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 66: 353–359.
KoranLM, AboujaoudeE, GamelNN (2009). Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 70: 1530–1535.
KronigMH, ApterJ, AsnisG, et al. (1999). Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder. J Clin Psychopharmacol 19: 172–176.
KushnerMG, WonKS, DonahueC, et al. (2007). d-Cycloserine augmented exposure therapy for obsessive compulsive disorder. Biol Psychiatry 62: 835–838.
LafleurDL, PittengerC, KelmendiB, et al. (2006). N-Acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl) 184: 254–256.
Lopez-IborJJ Jr., SaizJ, CottrauxJ, et al. (1996). Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder. Eur Neuropsychopharmacol 6: 111–118.
MainaG, AlbertU, SalviV, BogettoF (2004). Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. J Clin Psychiatry 65: 1365–1371.
MarazzitiD, Dell’OssoL, GemignaniA, et al. (2001). Citalopram in refractory obsessive-compulsive disorder: an open study. Int Clin Psychopharmacol 16: 215–219.
MarchJS, FrancesA, CarpenterD, KahnDA (1997). The Expert Consensus Guideline Series: treatment of obsessive-compulsive disorder. J Clin Psychiatry 58(Suppl 4): 3–72.
MarcyTR, BrittonML (2005). Antidepressant-induced sweating. Ann Pharmacother 39: 748–752.
MarksIM, SternRS, MawsonD, CobbJ, McDonaldR (1980). Clomipramine and exposure for obsessive compulsive rituals. Br J Psychiatry 136: 1–25.
MathSB, ReddyCJ (2007). Issues in the pharmacological treatment of obsessive-compulsive disorder. J Clin Pract 61: 1188–1197.
MavissakalianMR, PerelJM (2000). The side effects burden of extended imipramine treatment of panic disorder. J Clin Psychopharmacol 20: 547–555.
MontgomerySA (1980). Clomipramine in obsessional neurosis: a placebo controlled trial. Pharmaceut Med 1: 189–192.
MontgomerySA (1998). Psychopharmacology of obsessive-compulsive disorder. CNS Spectr 3(Suppl 1): 33–37.
MontgomerySA, McIntyreA, OsterheiderM, for the Lilly European OCD Study Group (1993). A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. Eur Neuropsychopharmacol 3: 143–152.
MontgomerySA, KasperS, SteinDJ, BangHK, LemmingOM (2001). Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol 16: 75–86.
MoretC, IsaacM, BrileyM (2009). Problems associated with long term treatment of selective serotonin reuptake inhibitors. J Psychopharmacol 23: 967–974.
MundoE, BianchiL, BellodiL (1997). Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study. J Clin Psychopharmacol 17: 267–271.
MundoE, MainaG, UslenghiC (2000). Multicentre, double-blind, comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 15: 69–76.
MundoE, RouillonF, FigueraML, StiglerM (2001). Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine. Hum Psychopharmacol 16: 461–446.
MurphyTK, SegarraA, StorchEA, GoodmanWK (2008). SSRI adverse events: how to monitor and manage. Int Rev Psychiatry 20: 203–208.
NinanPT, KoranLM, KievA, et al. (2006). High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. J Clin Psychiatry 67: 15–22.
NurnbergHG, HensleyPL, GelenbergAJ, et al. (2003). Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. JAMA 289: 56–64.
PaeCU, PatkarAA (2007). Paroxetine: current status in psychiatry. Expert Rev Neurother 7: 107–120.
PallantiS, QuercioliL, PaivaRS, KoranLM (1999).Citalopram for treatment-resistant obsessive-compulsive disorder. Eur Psychiatry 14: 101–106.
PallantiS, QuercioliL, KoranLM (2002). Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. J Clin Psychiatry 63: 796–801.
PallantiS, QuercioliL, BruscoliM (2004). Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. J Clin Psychiatry 65: 1394–1399.
PampaloniI, SivakumaranT, HawleyC, et al. (2009). High-dose selective serotonin reuptake inhibitors in OCD: a systematic retrospective case notes survey. J Psychopharmacol 2009 (epub ahead of print; doi:10.1177/0269881109104850).
Physicians Desk Reference (2006). Montvale NJ: PDR Network, Thomson http://www.pdr.net/login/Login.aspx (accessed 26 July 2010).
PiccinelliM, PiniS, BellantouonoC, et al. (1995). Efficacy of drug treatment in obsessive-compulsive disorder: a meta-analytic review. Br J Psychiatry 166: 424–443.
PierreJM, GuzeBH (2000). Benztropine for venlafaxine-induced night sweats. J Clin Psychopharmacol 20: 269.
PigottTA, PatoMT, BernsteinSE, et al. (1990). Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder: behavioral and biological results. Arch Gen Psychiatry 47: 926–932.
PittengerC, KrystalJH, CoricV (2006). Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. Neurotherapeutivs 3: 69–81.
PostemakM, ZimmermanM (2005). Dual reuptake inhibitors incur lower rates of tachyphylaxis than selective serotonin reuptake inhibitors. J Clin Psychiatry 66: 705–707.
RackM, ChirD (1970). Experience with intravenous clomipramine. In SalzmanL (ed.) Obsessional States and their Treatment with Anafranil (pp. 10–13). Macclesfield, UK: Geigy.
RasmussenBB, MaenpaaJ, PelkonenO, et al. (1995). Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 39: 151–159.
RasmussenS, HackettE, DuBoffE, et al. (1997). A 2-year study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 12: 309–316.
ReidS, BarbuiC (2010). Long term treatment of depression with selective serotonin reuptake inhibitors and newer antidepressants. BMJ 340: c1468.
RomanoS, GoodmanW, TamuraR, GonzalesJ (2001). Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo. J Clin Psychopharmacol 21: 46–52.
RosenRC, LaneRM, MenzaM (1999). Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 19: 67–85.
RuferM, HandI, AlslebenH, et al. (2005). Long-term course and outcome of obsessive-compulsive patients after cognitive-behavioral therapy in combination with either fluvoxamine or placebo: a 7-year follow-up of a randomized double-blind trial. Eur Arch Psychiatry Clin Neurosci 255: 121–128.
SassoDA, KalanithiPS, TruebloodKV, et al. (2006). Beneficial effects of the glutamate-modulating agent riluzole on disordered eating and pathological skin-picking behaviors. J Clin Psychopharmacol 26: 685–687.
SchruersK, KoningK, LuermansJ, HaackMJ, GriezE (2005). Obsessive-compulsive disorder: a critical review of therapeutic perspectives. Acta Psychiatr Scand 111: 261–271.
SeidmanSN, PesceVC, RooseSP (2003). High-dose sildenafil citrate for selective serotonin reuptake inhibitor-associated ejaculatory delay: open clinical trial. J Clin Psychiatry 64: 721–725.
SinclairLI, ChristmasDM, HoodSD, et al. (2009). Antidepressant-induced jitteriness/anxiety syndrome: systematic review. Br J Psychiatry 194: 483–490.
SkjelboE, BrosenK (1992). Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 34: 256–261.
SmeraldiE, ErzegovesiS, BianchiI, et al. (1992). Fluvoxamine vs clomopramine treatment in obsessive-compulsive disorder: a preliminary study. New Trends Exp Clin Psychiatry 8: 63–65.
SoomroGM (2003). Obsessive compulsive disorder. Clin Evidence 10: 1172–1187.
SoomroGM, AltmanDG, RajagopalS, Oakley BrowneM (2008). Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database of Systematic Reviews (1): CD001765.
SteinDJ, SpadaccniE, HollanderE (1995). Meta-analysisof pharmacotherapy trials for obsessive-compulsive disorder. Int Clin Psychopharmacol 10: 11–18.
SzegediA, WetzelH, LealM, HärtterS, HiemkeC (1996). Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data. J Clin Psychiatry 57: 257–264.
TamamL, OzpoyrazN (2002). Selective serotonin reuptake inhibitor discontinuation syndrome: a review. Adv Ther 19: 17–26.
The Medical Letter (2003). 45(Issue W1158B), June 9 http://www.medicalletter.org/restricted/articles/w1158b.pdf (access available to subscribers only).
ThorenP, AsbergM, CronholmB, JornestedtL, TraskmanL (1980). Clomipramine treatment in obsessive-compulsive disorder, a controlled trial. Arch Gen Psychiatry 37: 1281–1285.
TollefsonGD, RampeyAH Jr., PotvinJH, et al. (1994). A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 51: 559–567.
VallejoJ, OlivaresJ, MarcosT, BulbenaA, MenchonJM (1992). Clomipramine versus phenelzine in obsessive-compulsive disorder: a controlled clinical trial. Br J Psychiatry 161: 665–670.
VandelP, BoninB, LevequeE, SechterD and BizouardP (1997). Tricyclic antidepressant-induced extrapyramidal side effects. Eur Neuropsychopharmacol 7: 207–212.
WeinriebRM, AuriacombeM, LynchKG, LewisJD (2005). Selective serotonin re-uptake inhibitors and the risk of bleeding. Expert Opin Drug Saf 4: 337–344.
Yaryura-TobiasJA, NezirogluFA (1996). Venlafaxine in obsessive-compulsive disorder. Arch Gen Psychiatry 53: 653–654.
YonkersKA, WisnerKL, StewartDE, et al. (2009). The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol 114: 703–713.
ZajeckaJ, TracyKA, MitchellS (1997). Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry 58: 291–297.
ZimmermanM, ThongyT (2007). How often do SSRIs and other new-generation antidepressants lose their effect during continuation treatment? Evidence suggesting the rate of true tachyphylaxis during continuation treatment is low. J Clin Psychiatry 68: 1271–1276.
ZoharJ, JudgeR (1996). OCD Paroxetine Study Investigators: Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Br J Psychiatry 169: 468–474.